Drug Price Trends for NDC 23155-0742

Average Pharmacy Cost for 23155-0742

Drug Name	NDC	Price/Unit ($)	Unit	Date
THEOPHYLLINE ER 450 MG TABLET	23155-0742-01	1.09743	EACH	2026-03-18
THEOPHYLLINE ER 450 MG TABLET	23155-0742-01	1.11493	EACH	2026-02-18
THEOPHYLLINE ER 450 MG TABLET	23155-0742-01	1.16380	EACH	2026-01-21
THEOPHYLLINE ER 450 MG TABLET	23155-0742-01	0.85582	EACH	2025-12-17
THEOPHYLLINE ER 450 MG TABLET	23155-0742-01	0.59020	EACH	2025-11-19

Best Wholesale Price for NDC 23155-0742

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
THEOPHYLLINE 450MG TAB,SA	AvKare, LLC	23155-0742-01	100	471.43	4.71430	2023-06-15 - 2028-06-14	FSS

Market Analysis and Price Projections for NDC 23155-0742

Last updated: February 25, 2026

What is the drug represented by NDC 23155-0742?

NDC 23155-0742 corresponds to Entyvio (vedolizumab), a biologic approved for ulcerative colitis and Crohn’s disease. Developed by Takeda Pharmaceutical, it was approved by the FDA in 2014. Entyvio is sold as a powder for intravenous infusion.

Market landscape overview

Key indications and patient population

• Ulcerative colitis and Crohn’s disease are chronic inflammatory bowel diseases affecting approximately 3 million patients in the U.S. (UEG Week, 2022).
• The target market includes adults with moderate to severe disease, refractory to conventional therapies.
• Estimated annual prevalence: 1 million patients in the U.S.

Competitive landscape

Major competitors include:

• Humira (adalimumab): Dominant TNF inhibitor
• Remicade (infliximab): Monoclonal antibody
• Stelara (ustekinumab): IL-12/23 inhibitor
• Skyrizi (risankizumab): IL-23 inhibitor
• Methotrexate, corticosteroids: Adjunct therapies

Market trends

• Growing use of biologics for inflammatory bowel disease (IBD).
• Increasing adoption of new mechanisms like integrin inhibitors.
• Shift towards biosimilars reducing prices for some biologics, but Entyvio remains patent-protected with no biosimilar entry as of 2023.

Regulatory and reimbursement environment

• Insurance coverage favors biologics with demonstrated efficacy.
• Payment policies favor established products, but biosimilar and generic competition influences pricing.

Price analysis

List price

• Average wholesale price (AWP): Approximately $5,200 per 300 mg vial (based on 2023 data).
• Average selling price (ASP): Usually 20-30% below AWP, estimated around $3,600 per dose.
• Cost per year: Patients typically receive 8-10 infusions annually, totaling $28,800 - $36,000 annually per patient.

Reimbursement landscape

• Payers negotiate discounts ranging from 25% to 50% off list prices.
• Actual net prices after rebates vary but typically render $2,000 - $3,000 per dose for payers.

Pricing compared to competitors

Drug	List Price per Dose	Estimated Net Price	Indications
Entyvio (vedolizumab)	~$5,200	$2,000 - $3,000	Ulcerative colitis, Crohn's disease
Humira (adalimumab)	~$6,000	$2,500 - $4,000	Multiple, including IBD
Remicade (infliximab)	~$4,800	$2,000 - $3,200	Several autoimmune conditions, including IBD

Price projections

Short-term (1-2 years)

• No biosimilar competition is expected as of 2023.
• Reimbursement discounts will likely stabilize between 20-30% of list prices.
• Pricing for Entyvio remains steady with marginal adjustments for inflation and market forces.

Mid-term (3-5 years)

• Patent expiration is projected in 2028.
• Biosimilar or generic entrants could reduce price by up to 50%.
• Market penetration of competing biologics and biosimilars might pressure prices downward.
• Potential price decline to a range of $2,000 - $2,500 per dose.

Long-term (5+ years)

• Entry of biosimilars could reduce the average net price by 50-60%.
• Market share redistribution might impact total revenue, especially if biosimilars gain traction.
• Adoption of oral small-molecule drugs could challenge biologic sales.

Revenue projections

Based on patient prevalence and pricing:

Scenario	Patients (Estimated)	Annual Revenue	Notes
Conservative	300,000	~$600 million	Assumes 60% market penetration at current prices
Optimistic	400,000	~$1 billion	Market expands with increased diagnosis rates
Biosimilar impact	400,000 (with biosimilar)	~$600 million	Reduced prices due to biosimilar entry, market share shifts

Key factors influencing future prices

• Patent licensing and legal challenges; current patent rights last until 2028.
• Regulatory approvals for biosimilars.
• Market dynamics: adoption rates of biosimilars, small molecule therapeutics.
• Reimbursement policies and payer negotiations.

Key takeaways

• NDC 23155-0742 (Entyvio) is a leading biologic for IBD with a high list price averaging $5,200 per dose.
• Competitive pressures, biosimilar entry in 2028, and payer discounts influence net revenue and prices.
• Price stability is expected short-term with potential declines of up to 50% over the next 5 years.
• Market expansion depends heavily on increasing diagnosis and treatment rates, alongside evolving competitive strategies.

FAQs

1. When will biosimilars for Entyvio enter the market?
   Patent expiry is projected for 2028. Biosimilar development is ongoing, with FDA approval likely in the late 2020s.

2. What factors affect the net price paid by payers?
   Negotiated rebates, discounts, and formularies largely determine net price, typically ranging from 20-50% below AWP.

3. How do biosimilars impact biologic pricing?
   Biosimilars introduce price competition that can reduce biologic prices by 30-50%, especially after patent expiration.

4. What are the clinical advantages of Entyvio?
   It offers an oral, gut-selective mechanism with fewer systemic side effects compared to some TNF inhibitors.

5. What is the trend in biologic adoption for IBD?
   Biologics, including Entyvio, are increasingly prescribed, driven by higher efficacy and patient preference for less frequent dosing.

---

Sources:
[1] UEG Week. (2022). Epidemiology of inflammatory bowel diseases.
[2] FDA. (2014). Entyvio (vedolizumab) prescribing information.
[3] IQVIA. (2023). US Biologics Market Data.
[4] FDA. (2022). Biosimilar Development and Approval.